ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Patient Outcomes, Preferences, and Attitudes Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 340
Accessing Positive (but Not Negative) Online Reviews Is Associated with Increased Willingness to Take Medication
9:00AM-11:00AM
Abstract Number: 357
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
9:00AM-11:00AM
Abstract Number: 347
Disease Burden at One Academic Rheumatology Routine Care Setting Is Similar in Osteoarthritis (OA) and Rheumatoid Arthritis (RA) at First Visit but Significantly Greater in OA at a 6-Month Follow-up Visit
9:00AM-11:00AM
Abstract Number: 360
Evaluation of the Educational Needs in Argentinian Patients with Rheumatoid Arthritis Using the SpENAT Questionnaire
9:00AM-11:00AM
Abstract Number: 342
Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study
9:00AM-11:00AM
Abstract Number: 351
Integration of Electronically Captured Patient-Reported Outcomes in a Pediatric Rheumatology Clinic Visit
9:00AM-11:00AM
Abstract Number: 338
Measurement Properties of Paindetect, a Neuropathic Pain Screening Tool, for Evaluating Pain Phenotype in Patients with Rheumatoid Arthritis: Developing Neuropathic Pain Scale As a Measure of Treatment Outcome By Applying Rasch Analysis
9:00AM-11:00AM
Abstract Number: 361
Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
9:00AM-11:00AM
Abstract Number: 354
Multidomain Functional Assessment in a Cohort of Patients with Systemic Lupus Erythematosus: A Pilot Study
9:00AM-11:00AM
Abstract Number: 359
Nurse Telephone Education for Promoting a Treat-to-Target Approach in Recently Diagnosed Rheumatoid Arthritis Patients – a Preliminary Review
9:00AM-11:00AM
Abstract Number: 353
Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey
9:00AM-11:00AM
Abstract Number: 337
Patient-Reported Flares Were Correctly Predicted By an Algorithm Using Machine-Learning Statistics on Activity Tracker Data on Steps, in a Longitudinal 3-Month Study of 170 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA)
9:00AM-11:00AM
Abstract Number: 336
Patient–Reported Barriers to Achieving Rheumatoid Arthritis Disease Control
9:00AM-11:00AM
Abstract Number: 358
Patients and Physicians Have Different Perceptions of the Relative Bother of the Symptoms and Impacts on Daily Activities in Psoriasis and Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 350
Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State
9:00AM-11:00AM
Abstract Number: 339
Patients’ Attitudes and Experiences of Transitional Care in Paediatric Rheumatology: A Systematic Review of Qualitative Studies
9:00AM-11:00AM
Abstract Number: 362
Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
9:00AM-11:00AM
Abstract Number: 355
Perceptions and Outcomes of Pregnancy and Lactation in Patients with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 349
Preferences and Satisfaction in a Pediatric Multidisciplinary Infusion Center
9:00AM-11:00AM
Abstract Number: 356
Preliminary Real World Data on Switching Patterns between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry
9:00AM-11:00AM
Abstract Number: 335
Psoriatic Arthritis Patients Who Attain a Very Low Disease Activity State Have a Minimal Impact of the Disease on Their Lives
9:00AM-11:00AM
Abstract Number: 352
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
9:00AM-11:00AM
Abstract Number: 344
Real World Clinical Trial Comparing the Patient Reported Outcomes Measurement Information System Short Forms and Profiles to CDAI Disease Classification in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 348
The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome
9:00AM-11:00AM
Abstract Number: 345
The Patient Experience of Musculoskeletal Imaging Tests for Investigation of Inflammatory Arthritis: A Mixed Methods Study
9:00AM-11:00AM
Abstract Number: 341
Understanding Perceptions and Experience of Gout through Linguistic Analysis of Online Search Activities
9:00AM-11:00AM
Abstract Number: 346
What Are We Measuring? Influence of Contextual Factors on RAPID3 Scores in Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 343
What Is the Impact of Functional Medicine on Patient Reported Outcomes in Inflammatory Arthritis?
9:00AM-11:00AM
Abstract Number: 363
Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology